Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 13;11(1):16485.
doi: 10.1038/s41598-021-95176-3.

Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)

Affiliations

Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)

Ajeeta Anand et al. Sci Rep. .

Erratum in

Abstract

Hyperphosphataemia is treated with phosphate binders, which can cause adverse effects. Spray-dried synbiotic powder (SP) composed of Lactobacillus casei JCM1134 (a phosphate-accumulating organism; PAO) and Aloe vera is potentially a safer alternative for efficient phosphate removal. In this study, a novel strategy was developed; lysine-derivatized deacetylated A. vera (DAVK) was synthesised and fabricated on phosphate-deficient PAO (PDP) for efficient phosphate transfer and then spray-dried with the supernatant of DAV centrifugation to form a sacrificial layer on PDP for SP integrity during gastric passage. In vitro experiments revealed that PAO removed only 1.6% of the phosphate from synthetic media, whereas SP removed 89%, 87%, and 67% (w/v) of the phosphate from milk, soft drink, and synthetic media, respectively, confirming the protective role of A. vera and efficient phosphate transport. Compared with commercial binders, SP effectively removed phosphate from synthetic media, whereas SP and CaCO3 exhibited comparative results for milk and soft drink. Importantly, CaCO3 caused hypercalcaemia. Thus, the described SP presents a promising tool to prevent hyperphosphataemia. This study also revealed a novel factor: diets of patients with chronic kidney disease should be monitored to determine the optimal phosphate binders, as phosphate removal performance depends on the accessible phosphate forms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Experimental procedure for spray dried synbiotic powder (SP) formulation.
Figure 2
Figure 2
Fourier-transform infrared spectroscopy (FT-IR) analysis of Aloe vera modification. (a) Untreated Aloe vera, (b) deacetylated A. vera (DAV), and (c) lysine derivative of DAV (DAVK).
Figure 3
Figure 3
Unreacted lysine in lysine derivative of deacylatisation Aloe vera (DAVK) over time. In the reaction mixture, deacylated A. vera (DAV, 1 g) and lysine (70 mg) reacted under optimised conditions and significant p-values (p < 0.002 by two-tailed ANOVA, with n = 3 and alpha value of 0.95) were obtained and the standard errors are shown as error bars.
Figure 4
Figure 4
Scanning electron microscopy (SEM) analysis of Lactobacillus casei JCM1134 as phosphate-deficient cells (PDP) and under stepwise encapsulation conditions. (a) PDP, (b) lysine (K) derivative of deacetylated A. vera (DAVK)-encapsulated PDP, and (c) spray-dried synbiotic formulation (SP).
Figure 5
Figure 5
Comparison of spray-dried synbiotic formulation with commercial phosphate binders. Phosphate-rich foods that were used included milk, a soft drink, and synthetic media. Significant p-values (p < 0.05 by two-tailed ANOVA, with n = 3 and alpha value of 0.95) were obtained and standard errors are shown as error bars.
Figure 6
Figure 6
A schematic diagram of a gastrointestinal simulation system for the evaluation of different phosphate removing agents from the in vitro broth, which contains phosphate-rich sources.

Similar articles

Cited by

References

    1. Jespersen B, et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1–84), and bone mineral content in dialysis patients. Nephrol. Dial. Transplant. 1991;6:98–104. - PubMed
    1. Malberti F. Hyperphosphataemia: Treatment options. Drugs. 2013 doi: 10.1007/s40265-013-0054-y. - DOI - PubMed
    1. David E. Leaf & Myles Wolf. Physiologic–based approach to the evaluation of a patient with hyperphosphatemia. 61, 330–336 (2013). - PMC - PubMed
    1. Peres, L. A., lbert, B., Pércio, P. & Paul, V. Mineral and bone disorder and vascular calcification in patients with chronic kidney disease. Jornal brasileiro de nefrologia 36, 201–207 (2014). - PubMed
    1. Nagata M, et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama Study. Nephrol. Dial. Transplant. 2010;25:2557–2564. - PubMed

Publication types

LinkOut - more resources